Trials / Terminated
TerminatedNCT00036231
Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Efficacy, Safety and Tolerability of RG1068 (Synthetic Human Secretin) in Children With Autism and Gastrointestinal Dysfunction
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Repligen Corporation · Industry
- Sex
- All
- Age
- 32 Months – 59 Months
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine the effect of multiple doses of secretin on autism.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RG1068 (Synthetic Human Secretin) |
Timeline
- Start date
- 2002-04-01
- First posted
- 2002-05-09
- Last updated
- 2005-11-21
Source: ClinicalTrials.gov record NCT00036231. Inclusion in this directory is not an endorsement.